PFA Audited Financial Results
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ajanta Pharma reported strong Q4 FY26 results with revenue up 21% to ₹1,422 crore and PAT up 18% to ₹267 crore. Full year FY26 revenue grew 17% to ₹5,453 crore with PAT of ₹1,056 crore, up 15%. Excluding mark-to-market forex losses of ₹103 crore, EBITDA grew 18% with a margin of 27%. The US generics segment was a standout, with Q4 revenue jumping 56% and FY26 growing 49% to ₹1,557 crore. India branded generics grew 14% for FY26, outperforming IPM growth by 33%. The auditors issued an unmodified opinion but included an Emphasis of Matter regarding Income Tax search operations in August 2025 and a subsequent notice under Section 158BC for block period April 2019 to November 2025 — impact remains unascertained. ROCE stands at a healthy 33%.
Strong all-round performance with US generics driving growth, but the unresolved Income Tax search matter represents a contingent risk that investors should monitor. The 21% Q4 revenue growth qualifies as a significant positive signal.